Silexion Therapeutics Corp

Silexion Therapeutics Corp is a U.S.-listed holding company whose operations are conducted primarily through its subsidiary Silexion, a clinical-stage biotechnology company focused on RNA-interference therapeutics for KRAS-driven cancers. Its lead program, SIL204, is being developed as a locally administered siRNA treatment for locally advanced pancreatic cancer, alongside a broader pipeline of oncology product candidates.

2.41

2.41

— Silexion Therapeutics Corp
%
Lead therapeutic candidate100% SIL204 and related siRNA-based oncology treatments targeting KRAS-driven tumors.
Pre-clinical development0% Discovery, toxicology, and translational work supporting future product candidates.
Clinical development0% Human trial planning and execution for oncology drug candidates.

Silexion does not yet sell commercial products; its near-term counterparties are clinical investigators, trial sites,...

  • Clinical development partnersprimary

    Trial sites, investigators, CROs, and research collaborators that support SIL204 testing and data generation.

  • Regulatory authoritiesprimary

    U.S., EU, and other regulators that review toxicology, clinical, and approval submissions.

  • Future oncology providersemerging

    Hospitals, oncologists, and cancer centers that could use approved KRAS-targeted therapies.

The company is organized as a Cayman Islands holding company with operations primarily conducted through Silexion,...

  • •Cayman Islands holding-company structure
  • •Operations primarily through the Silexion subsidiary
  • •Historical financing support from Israeli Innovation Authority grants
  • •Planned regulatory pathways in the U.S. and EU
  • •No disclosed product-revenue geography yet

Silexion’s strategy is centered on advancing SIL204 through pre-clinical work, toxicology, and clinical trials while...

01
Advance SIL204 into clinical testingshort-term

Clinical data are required to validate the therapeutic concept and support future approval.

02
Secure regulatory and IP positionmedium-term

Regulatory milestones and patent protection are central to value creation in biotech.

03
Fund development and broaden pipelineshort-term

The company needs capital to sustain R&D and diversify beyond a single lead asset.

Silexion is exposed to the core risks of clinical-stage biotechnology: development failure, regulatory delay, and the...

critical

Clinical development failure

SIL204 must generate convincing safety and efficacy data before approval is possible.

Scope
Lead program SIL204
Materiality
high
high

Capital dependence

The company has not generated revenue and expects substantial funding needs.

Scope
R&D and trial funding
Materiality
high
high

Regulatory risk

Approval depends on successful toxicology, clinical, and submission outcomes across jurisdictions.

Scope
U.S., EU, and other territories
Materiality
high
high

Pipeline concentration

Value is heavily tied to one lead candidate and a narrow oncology platform.

Scope
SIL204 and KRAS-focused programs
Materiality
high
medium

Dilution and market-price volatility

Equity and warrant financings can dilute holders and affect share price.

Scope
Public-company financing
Materiality
medium
Valuation of promissory notes
Can create non-cash gains or losses and affect liabilities
Fair value estimates
Affects balance sheet values and earnings volatility
Research and development expense timing
Drives operating loss comparability across quarters
Share-based compensation and warrant accounting
Affects reported earnings and per-share metrics

Silence Therapeutics plc

SLN · Pharmaceutical Preparations

IO Biotech, Inc.

IOBTQ · Pharmaceutical Preparations

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

Cyclerion Therapeutics, Inc.

CYCN · Pharmaceutical Preparations

DiaMedica Therapeutics Inc.

DMAC · Pharmaceutical Preparations

: 29/04/2026